Warning: CMEcorner.com will not work properly with JavaScript disabled! Please enable javascript before proceeding.
Warning: CMEcorner.com will not work properly with JavaScript disabled! Please enable javascript before proceeding.
Start the program at
the bottom of this page
Clinical Case Challenge: Recurrent COPD Exacerbations
Release Date: October-30-09
Credit Expiration Date: October-30-10
Medical Communications Media, Inc.
This educational activity is designed to meet the needs of pulmonologists, allergy/immunology specialists, primary care providers, nurse practitioners/advance practice nurses, and other healthcare providers with an interest in the treatment of chronic obstructive pulmonary disease (COPD).
0.5
Clinical Case Challenge (Online)
As the fourth leading cause of death in the United States, chronic obstructive pulmonary disease (COPD) is a major and increasingly prevalent public health issue. Although COPD has no cure, its progression can be slowed and its symptoms managed through appropriate treatment. COPD management guidelines have been issued by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and American Thoracic Society/European Respiratory Society. Regimens for COPD can include inhaled pharmacologic therapy with short- or long-acting bronchodilators, inhaled corticosteroids, combination agents pulmonary rehabilitation, disease management, and supplemental oxygen. The appropriate treatment regimen can provide symptomatic benefit to patients with COPD and increase their quality of life and daily functioning. This activity has been designed to demonstrate the challenges associated with the management of COPD. This activity has been designed to demonstrate methods to address the challenges associated with the management of COPD.
Upon completion of this educational activity, the participant should be able to:
1.
Apply updated COPD guidelines when selecting maintenance therapies.
2.
Implement treatment strategies to reduce COPD exacerbations.
3.
Discuss ways to manage common comorbidities in patients with COPD.
James F. Donohue, MD
Professor of Medicine
Chief, Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activities or with the commercial supporter of these continuing education activities. Identified conflict of interest is resolved by AKH prior to accreditation of the activities. AKH planners and reviewers have no relevant financial relationships to disclose.
James F. Donohue, MD, discloses that he has served as a consultant to AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., DEY, L.P., Forest Laboratories, Inc., GlaxoSmithKline, Novartis, Nycomed, and Sepracor Inc. Dr. Donohue also discloses that he has served on the speakers bureaus of AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., and GlaxoSmithKline. He has received research support from Boehringer Ingelheim Pharmaceuticals, Inc., Centocor, and Novartis.
PHYSICIANS: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 0.5
AMA PRA Category 1 Credit
TM
. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NURSES: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
AKH Inc. designates this educational activity for 0.5 contact hour (0.05 CEU). Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA.
.
$0.00
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or AstraZeneca. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.
